1. RenovoRx's abstract accepted for ASCO GI 2026, presenting novel therapy data. 2. Study compares gemcitabine delivery methods, favoring intra-arterial approach. 3. RenovoCath device shows decreased side effects versus standard chemotherapy. 4. Phase III TIGeR-PaC trial ongoing, targeting advanced pancreatic cancer. 5. RenovoRx reports $900,000 revenues from RenovoCath sales in 2025.
FAQ
Why Bullish?
The acceptance of the abstract and clinical trial progress present potential for positive market reception, similar to past FDA clearances boosting stock prices in biotech companies.
How important is it?
The article highlights critical clinical advancements and revenue generation, crucial for investor confidence; historical analogs indicate upcoming presentations boost stocks.
Why Short Term?
Upcoming presentation at ASCO GI in January could lead to immediate investor interest in RNXT, mimicking past scenarios where conference presentations resulted in stock upticks.
RenovoRx Announces Acceptance of Clinical Data Abstract at ASCO Gastrointestinal Cancers Symposium 2026
MOUNTAIN VIEW, Calif., Dec. 11, 2025 – RenovoRx, Inc. (Nasdaq: RNXT), a leader in innovative oncology therapies, has announced the acceptance of its clinical data abstract for presentation at the prestigious American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026.
Abstract Presentation Details
RenovoRx will showcase findings from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial. The sub-study, entitled “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial,” will compare systemic drug levels of gemcitabine administered via the Company’s FDA-cleared RenovoCath® device against the traditional intravenous chemotherapy during the treatment of locally advanced pancreatic cancer (LAPC).
- Presentation Date: January 9, 2026
- Time: 11:30 AM-1:00 PM PT and 5:00 PM-6:00 PM PT
- Location: Moscone West Building, San Francisco, CA
- Abstract Number: 732
- Poster Board Number: K2
- Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
- Presenter: Dr. Paula M. Novelli, University of Pittsburgh Medical Center
Implications of Study Findings
Dr. Ramtin Agah, Chief Medical Officer of RenovoRx, commented, “This clinical data abstract further contributes to the scientific basis for the reported decreased clinical side effect profile with our approach to targeted drug delivery via the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform and IAG compared to systemic intravenous therapy. Our findings demonstrate that systemic drug levels are reduced when using our device versus standard treatment.”
About RenovoCath® and TIGeR-PaC
RenovoCath® is a patented device designed for the precise delivery of therapeutic agents while aiming to minimize harmful side effects associated with systemic therapies. The TIGeR-PaC clinical trial, currently running as a Phase III randomized multi-center study, evaluates this innovative therapy platform specifically for LAPC.
RenovoRx's Mission and Commercial Efforts
RenovoRx, Inc. (Nasdaq: RNXT) aims to address significant medical needs in cancer treatment. The TAMP™ therapy platform seeks to enhance therapeutic efficacy while reducing toxicity compared to traditional treatments. In December 2024, the company received its first commercial orders for RenovoCath, generating approximately $900,000 in revenues during the first nine months of 2025, highlighting strong interest in its innovative approach.
Future Outlook and Market Position
Looking forward, RenovoRx plans to expand its operational capabilities and meet increasing demand for its technology, whether independently or through partnerships with medical device companies. As the U.S. FDA progresses with its investigation of the intra-arterial gemcitabine under the investigational new drug application, market potential remains robust.